74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
MiNK Therapeutics
Closed
9.91 6.44
Overview
Share price change
24h
Min
9.73
Max
9.91
Income | 895K -1.8M |
|---|---|
EPS | -0.5 |
Employees | 31 |
EBITDA | 1M -1.8M |
Recommendations | Buy |
|---|---|
12 Months Forecast | -30.69 downside |
Market Cap | 38M |
|---|---|
Previous open | 3.47 |
Previous close | 9.91 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
MiNK Therapeutics Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
MiNK Therapeutics Forecast
Price Target
By TipRanks
-30.69% downside
12 Months Forecast
Average 7 USD -30.69%
High 7 USD
Low 7 USD
Based on 1 Wall Street analysts offering 12 month price targets forMiNK Therapeutics - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
